Absci Corporation and AstraZeneca have teamed up to fast-track the development of a potential new cancer treatment, an AI-designed antibody, using Absci’s Integrated Drug Creation™ platform. Absci will provide the AI expertise while AstraZeneca offers its oncology expertise. The platform will use a feedback loop including data collection, AI-driven design, and wet-lab validation.
Hacker Exploits Claude AI to Automate Cyberattacks on 17 Companies – WebProNews
Hacker Exploits Claude AI to Automate Cyberattacks on 17 Companies WebProNews
